STOCK TITAN
  1. Home
  2. News
  3. OSA

ProSomnus, Inc. - OSA STOCK NEWS

Welcome to our dedicated page for ProSomnus news (Ticker: OSA), a resource for investors and traders seeking the latest updates and insights on ProSomnus stock.

ProSomnus, Inc. Common Stock (symbol: OSA) is a leading provider of non-CPAP therapy solutions for the treatment of Obstructive Sleep Apnea (OSA). This serious medical condition affects over 1 billion people globally and is linked with several comorbidities such as heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus specializes in creating precision intraoral medical devices that are designed to fit the unique anatomy and treatment plans of each patient.

The company’s products are non-invasive, easy to use, and preferred by patients. They have demonstrated high levels of efficacy, safety, adherence, and overall positive outcomes in numerous clinical studies. ProSomnus devices are FDA-cleared, patented, and are covered by commercial medical insurance, Medicare, TRICARE, and many government-sponsored healthcare plans worldwide. This coverage extends to over 200 million lives.

Recent achievements include additional clinical research indicating that patients using ProSomnus devices have fewer apnea-hypopnea index events per hour, alongside strong treatment adherence. ProSomnus continues to develop and enhance their product offerings, providing cutting-edge solutions for those suffering from OSA.

For the latest updates, financial results, and news, contact Investor Relations or Media Relations through the provided contact details.

  • Recent clinical research shows decreased apnea-hypopnea index events per hour with strong treatment adherence using ProSomnus devices.
  • FDA-cleared and patented products
  • Coverage by major insurance plans, including Medicare and TRICARE
  • Innovative non-CPAP therapy solutions for Obstructive Sleep Apnea
News

ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results

Rhea-AI Summary
ProSomnus, Inc. (NASDAQ: OSA) announced record revenues of $7.8 million for Q4 and $27.7 million for fiscal year 2023, marking an increase of 35% and 43% respectively. The company focused on expense reductions, demonstrated technical feasibility of its Next Generation Remote Patient Monitoring device, and submitted a 510(k) Premarket Notification for label expansion. Financially, revenues increased driven by precision devices adoption, sales, and marketing investments. However, cost of revenue and expenses also increased, impacting the bottom line.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
earnings
-
News

ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

Rhea-AI Summary
ProSomnus, Inc. (OSA) delays 2023 Q4 and full year financial results release and investor call, rescheduled for March 26, 2024. The company also cancels attendance at the Roth Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
earnings
-
News

ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea

Rhea-AI Summary
ProSomnus, Inc. (NASDAQ: OSA) announces successful pilot study results for its Next Generation Remote Patient Monitoring device for Obstructive Sleep Apnea. The innovative device accurately monitors SpO2, paving the way for personalized and preventative sleep medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.63%
Tags
none
News

ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024

Rhea-AI Summary
ProSomnus, Inc. (NASDAQ: OSA) will report its Q4 and fiscal year 2023 financial results and provide a business update at the 36th Annual ROTH Conference. CEO Len Liptak and CFO Brian Dow will host a conference call and participate in investor meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.02%
Tags
earnings
-
News

ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA

Rhea-AI Summary
ProSomnus, Inc. announced that the FDA has accepted its premarket notification for the ProSomnus EVO precision medical device for the treatment of severe obstructive sleep apnea. The clinical data submitted by the Company demonstrated significant improvements in patients' AHI, ODI, and sleep apnea specific hypoxic burden without patient preselection or excluding patients with concentric collapse airway profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.54%
Tags
none
-
News

ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices

Rhea-AI Summary
ProSomnus, Inc. is well-positioned to support patients with Obstructive Sleep Apnea (OSA) following the discontinuation of CPAP devices by Philips Respironics. The company offers precision intraoral devices with excellent efficacy and patient preference. ProSomnus is ready to facilitate access to high-quality healthcare for millions of patients suffering from untreated OSA, providing a non-invasive and comfortable alternative to traditional CPAP therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
News

ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea

Rhea-AI Summary
ProSomnus, Inc. (OSA) welcomes UnitedHealthcare's updated medical policy for obstructive and central sleep apnea, which establishes oral appliance therapy as a prerequisite for Implantable Hypoglossal Nerve Stimulation. Recent research and data show that modern, precision oral appliances are effective, safe, and non-invasive, with a high level of patient satisfaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
none
-
News

Data Published by Cureus Journal of Medical Science Shows Successful Treatment of Obstructive Sleep Apnea with ProSomnus Precision Oral Appliance Devices

Rhea-AI Summary
ProSomnus, Inc. (NASDAQ: OSA) Successfully Treats OSA Patients with Precision Oral Appliance Therapy, New Clinical Research Shows
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
57.65%
Tags
none
-
News

ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results

Rhea-AI Summary
ProSomnus, Inc. (OSA) reports record quarterly revenue of $7.1 million, marking a 41.5% year-over-year increase and seventh consecutive quarter of sequential revenue growth. The company also achieved a 45.7% increase in revenues for the nine months ended 2023. ProSomnus continues to advance in clinical studies and achieved 13485:2016 Certification from Intertek.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
earnings
News

ProSomnus Announces Third Quarter 2023 Investor Call and Business Update

Rhea-AI Summary
ProSomnus, Inc. (NASDAQ: OSA) will report its third quarter financial results on November 9, 2023. The conference call will be hosted by CEO Len Liptak and CFO Brian Dow at 1:30 pm PT / 4:30 pm ET. Interested parties can register for the conference call and access the live webcast through the ProSomnus website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.4%
Tags
earnings

FAQ

What is the current stock price of ProSomnus (OSA)?

The current stock price of ProSomnus (OSA) is $0.47 as of April 17, 2024.

What is the market cap of ProSomnus (OSA)?

The market cap of ProSomnus (OSA) is approximately 8.2M.

What does ProSomnus, Inc. do?

ProSomnus, Inc. provides non-CPAP therapy solutions for the treatment of Obstructive Sleep Apnea using precision intraoral medical devices.

What is Obstructive Sleep Apnea (OSA)?

OSA is a serious medical condition affecting over 1 billion people worldwide, linked to comorbidities like heart failure, stroke, and type 2 diabetes.

Are ProSomnus devices FDA approved?

Yes, ProSomnus devices are FDA-cleared and patented.

What kind of insurance covers ProSomnus devices?

ProSomnus devices are covered by commercial medical insurance, Medicare, TRICARE, and many government-sponsored healthcare plans worldwide.

How effective are ProSomnus devices?

ProSomnus devices have shown high levels of efficacy, safety, and adherence in multiple clinical studies.

Can I contact ProSomnus for investor relations?

Yes, you can contact Mike Cavanaugh at +1.617.877.9641 or via email at Mike.Cavanaugh@westwicke.com.

Who should I contact for media inquiries?

For media inquiries, contact Heather Whalen at +1.925.360.2990 or via email at HWhalen@ProSomnus.com.

What recent achievements has ProSomnus made?

Recent clinical research indicates patients using ProSomnus devices have decreased apnea-hypopnea index events per hour with strong treatment adherence.

Where can I find ProSomnus's financial results?

You can contact Investor Relations or visit their official website for the latest financial results.

How can I learn more about ProSomnus's products?

Visit www.ProSomnus.com for detailed information about their products and solutions for Obstructive Sleep Apnea.

Stock OSA logo
ProSomnus, Inc.

Nasdaq:OSA

OSA Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

OSA Stock Data

8.18M
17.39M
20.64%
57.01%
0.42%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
PLEASANTON